Abstract Number: 1999 • 2015 ACR/ARHP Annual Meeting
Improvement in Mortality in RA Compared to the General Population – Closing the Mortality Gap
Background/Purpose: Increased mortality in RA is believed to be a consequence of inflammation. With improved treatment, mortality would be expected to decrease over time. The…Abstract Number: 2000 • 2015 ACR/ARHP Annual Meeting
Immune Response Against  β2GPI Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by the presence of arterial and venous thrombosis, and by recurrent abortions, in patients with persistent presence of autoantibodies…Abstract Number: 2001 • 2015 ACR/ARHP Annual Meeting
Reduction of HLA Class II Expression and Beta-2-Glycoprotein I Presentation By Fluvastatin in Vitro and in Vivo: Possible Mechanism of Statin-Induced-Deprocoagulation in the Antiphospholipid Syndrome
Background/Purpose: Human leukocyte antigen (HLA)-DRB1*07:01 is one of the susceptibility alleles for antiphospholipid syndrome (APS). Recently we have reported that beta-2-glycoprotein I (b2GPI) /HLA class…Abstract Number: 2002 • 2015 ACR/ARHP Annual Meeting
Dnase Treatment Protects Against DVT Formation in a Mouse Model of Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid antibodies, especially those targeting beta-2-glycoprotein I (β2GPI), have been shown to amplify thrombosis in mice. However, most published models have relied on endothelial…Abstract Number: 2003 • 2015 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome Is Characterized By Endothelial Progenitor Dysfunction and a Type I Interferon Signature
Background/Purpose: Patients with primary antiphospholipid syndrome (APS) are at risk for endothelial dysfunction and accelerated atherosclerosis. In systemic lupus erythematosus (SLE), there is a well-established…Abstract Number: 2004 • 2015 ACR/ARHP Annual Meeting
Procoagulant Property of a Novel Patient-Derived Autoimmune IgG Type Monoclonal Anticardiolipin Antibody That Binds to Beta 2 Glycoprotein Domain I but Not to Total Beta 2 Glycoprotein I Molecule
Background/Purpose: Anti-cardiolipin/β2 glycoprotein I (aCL/β2GPI) antibodies are representative antiphospholipid antibodies(aPLs) that target the complex of cardiolipin (or anionic molecules) and β2GPI. However, aCL is often regarded…Abstract Number: 2005 • 2015 ACR/ARHP Annual Meeting
Circulating Mirnas As Potential Disease Biomarkers in Antiphospholipid Syndrome Patients
Background/Purpose: Epigenetic anomalies are emerging as striking pathogenic features of autoimmune disorders. MicroRNAs (miRNAs) are small non-coding RNAs with a key role in regulatory networks that…Abstract Number: 2006 • 2015 ACR/ARHP Annual Meeting
Effect Size of the Anti-Aggrecanase-2 Monoclonal Antibody CRB0017 in Rodent Models of Osteoarthritis
Background/Purpose : There is huge interest in the family of “A Disintegrin And Metalloproteinase with ThromboSpondin motifs” (ADAMTS) proteinases, especially aggrecanase-2 (ADAMTS-5), as therapeutic targets…Abstract Number: 2007 • 2015 ACR/ARHP Annual Meeting
Discovery of an Intra-Articular Injection Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Disease Modifying Treatment for Knee Osteoarthritis
Background/Purpose: Wnt has a key role in the formation of bone, cartilage and synovium. Increased Wnt signaling may contribute to initiation and progression of osteoarthritis…Abstract Number: 2008 • 2015 ACR/ARHP Annual Meeting
WISP1 Aggravates Osteoarthritis By Modulation of TGF-β Signaling and Positive Regulation of Canonical Wnt Signaling
Background/Purpose: Many osteoarthritis (OA) patients show synovial activation, which is suggested to be involved in joint destruction. Previously, we found synovial overexpression of Wnt ligands in experimental…Abstract Number: 2009 • 2015 ACR/ARHP Annual Meeting
CC-Chemokine Receptor 7 (CCR7) Deficiency Reduces Early Structural and Functional Features of Disease in a Murine Model of Osteoarthritis
Background/Purpose: Synovial expression of CCR7 has been associated with inflammation and severity of symptoms in patients with meniscal tears and early osteoarthritis (OA). This receptor…Abstract Number: 2010 • 2015 ACR/ARHP Annual Meeting
Adenosine A2A Receptor, but Not A2B Receptor, Deletion Leads to Development of Osteoarthritis (OA) in Mice and Administration of a Liposomal Suspension of Adenosine Prevents/Treats Osteoarthritis in Rats
Background/Purpose: Adenosine, acting at its receptors, regulates chondrocyte function and inflammation, two components of OA. Mice lacking adenosine A2A receptors (A2AR) have increasing difficulty walking…Abstract Number: 2011 • 2015 ACR/ARHP Annual Meeting
Disruption of the Molecular Clock in Mesenchymal Cells Causes an Osteoarthritis-like Disease in Mice
Background/Purpose: Tissue-intrinsic circadian molecular clocks control many physiological processes. The function of these clocks in cells of the musculoskeletal system and their contribution to disease…Abstract Number: 2012 • 2015 ACR/ARHP Annual Meeting
TNF Confers Pathogenic Memory in Synovial Fibroblasts Via Chromatin Remodeling, NF-Kb-Dependent Transcription and MAPK-Mediated mRNA Stabilization
Background/Purpose: We investigated mechanisms driving pathogenic behavior of synovial fibroblasts (FLS) in rheumatoid arthritis (RA). Methods: FLS from RA patients (1987 classification criteria) were extracted.…Abstract Number: 2013 • 2015 ACR/ARHP Annual Meeting
TIARP Attenuates Autoantibody-Mediated Arthritis Via the Suppression of Neutrophil Infiltration into the Joint
Background/Purpose: TIARP (TNFα-induced adipose-related protein) is dominantly expressed in macrophages (Mφ), neutrophils (PMN) and fibroblast-like synoviocytes (FLS). Recently, we found that TIARP functions as a…
ACR Meeting Abstracts